These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 19135118)

  • 61. Late administration of plasmid DNA by intradermal electroporation efficiently boosts DNA-primed T and B cell responses to carcinoembryonic antigen.
    Bråve A; Hallengärd D; Gudmundsdotter L; Stout R; Walters R; Wahren B; Hallermalm K
    Vaccine; 2009 Jun; 27(28):3692-6. PubMed ID: 19428161
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Recombinant retrovirus-like particle forming DNA vaccines in prime-boost immunization and their use for hepatitis C virus vaccine development.
    Desjardins D; Huret C; Dalba C; Kreppel F; Kochanek S; Cosset FL; Tangy F; Klatzmann D; Bellier B
    J Gene Med; 2009 Apr; 11(4):313-25. PubMed ID: 19248137
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Elimination of immunodominant epitopes from multispecific DNA-based vaccines allows induction of CD8 T cells that have a striking antiviral potential.
    Riedl P; Wieland A; Lamberth K; Buus S; Lemonnier F; Reifenberg K; Reimann J; Schirmbeck R
    J Immunol; 2009 Jul; 183(1):370-80. PubMed ID: 19542448
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Live attenuated measles vaccine expressing HIV-1 Gag virus like particles covered with gp160DeltaV1V2 is strongly immunogenic.
    Guerbois M; Moris A; Combredet C; Najburg V; Ruffié C; Février M; Cayet N; Brandler S; Schwartz O; Tangy F
    Virology; 2009 May; 388(1):191-203. PubMed ID: 19345390
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Improved genetic stability of recombinant yellow fever 17D virus expressing a lentiviral Gag gene fragment.
    de Santana MG; Neves PC; dos Santos JR; Lima NS; dos Santos AA; Watkins DI; Galler R; Bonaldo MC
    Virology; 2014 Mar; 452-453():202-11. PubMed ID: 24606697
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Immunogenicity and growth inhibitory efficacy of the prime-boost immunization regime with DNA followed by recombinant vaccinia virus carrying the P29 gene of Babesia gibsoni in dogs.
    Fukumoto S; Tamaki Y; Igarashi I; Suzuki H; Xuan X
    Exp Parasitol; 2009 Dec; 123(4):296-301. PubMed ID: 19712674
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Immunogenicity of an HIV-1 gag DNA vaccine carried by attenuated Shigella.
    Xu F; Hong M; Ulmer JB
    Vaccine; 2003 Jan; 21(7-8):644-8. PubMed ID: 12531333
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [A kinetic study of gamma interferon production in herpes simplex virus-1 DNA prime-protein boost regimen comparing to DNA or subunit vaccination].
    Arefian E; Bamdad T; Soleimanjahi H; Akhood MR; Parsania M; Ghaemi A
    Mol Biol (Mosk); 2009; 43(3):422-8. PubMed ID: 19548528
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Vaccination with combination of Fit3L and RANTES in a DNA prime-protein boost regimen elicits strong cell-mediated immunity and antitumor effect.
    Song S; Liu C; Wang J; Zhang Y; You H; Wang Y; Liu F; Sun S
    Vaccine; 2009 Feb; 27(7):1111-8. PubMed ID: 19100302
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Adenovirus 5- and 35-based immunotherapy enhances the strength but not breadth or quality of immunity during chronic SIV infection.
    Soloff AC; Liu X; Gao W; Day RD; Gambotto A; Barratt-Boyes SM
    Eur J Immunol; 2009 Sep; 39(9):2437-49. PubMed ID: 19670380
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Vaccine-induced, simian immunodeficiency virus-specific CD8+ T cells reduce virus replication but do not protect from simian immunodeficiency virus disease progression.
    Engram JC; Dunham RM; Makedonas G; Vanderford TH; Sumpter B; Klatt NR; Ratcliffe SJ; Garg S; Paiardini M; McQuoid M; Altman JD; Staprans SI; Betts MR; Garber DA; Feinberg MB; Silvestri G
    J Immunol; 2009 Jul; 183(1):706-17. PubMed ID: 19542473
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Combining DNA technologies and different modes of immunization for induction of humoral and cellular anti-HIV-1 immune responses.
    Bråve A; Hallengärd D; Malm M; Blazevic V; Rollman E; Stanescu I; Krohn K
    Vaccine; 2009 Jan; 27(2):184-6. PubMed ID: 18992294
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Systemic DNA immunization against ovine lentivirus using particle-mediated epidermal delivery and modified vaccinia Ankara encoding the gag and/or env genes.
    Niesalla H; de Andrés X; Barbezange C; Fraisier C; Reina R; Arnarson H; Biescas E; Mazzei M; McNeilly TN; Liu C; Watkins C; Perez M; Carrozza ML; Bandecchi P; Solano C; Crespo H; Glaria I; Huard C; Shaw DJ; de Blas I; de Andrés D; Tolari F; Rosati S; Suzan-Monti M; Andrésdottir V; Torsteinsdottir S; Petursson G; Badiola J; Lujan L; Pepin M; Amorena B; Blacklaws B; Harkiss GD
    Vaccine; 2009 Jan; 27(2):260-9. PubMed ID: 18984025
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Use of B7 costimulatory molecules as adjuvants in a prime-boost vaccination against Visna/Maedi ovine lentivirus.
    de Andrés X; Reina R; Ciriza J; Crespo H; Glaria I; Ramírez H; Grilló MJ; Pérez MM; Andrésdóttir V; Rosati S; Suzan-Monti M; Luján L; Blacklaws BA; Harkiss GD; de Andrés D; Amorena B
    Vaccine; 2009 Jul; 27(34):4591-600. PubMed ID: 19538997
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Evaluation of a prime-boost vaccine schedule with distinct adenovirus vectors against malaria in rhesus monkeys.
    Rodríguez A; Mintardjo R; Tax D; Gillissen G; Custers J; Pau MG; Klap J; Santra S; Balachandran H; Letvin NL; Goudsmit J; Radosević K
    Vaccine; 2009 Oct; 27(44):6226-33. PubMed ID: 19686691
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Determination of a major histocompatibility complex class I restricting simian immunodeficiency virus Gag241-249 epitope.
    Tsukamoto T; Dohki S; Ueno T; Kawada M; Takeda A; Yasunami M; Naruse T; Kimura A; Takiguchi M; Matano T
    AIDS; 2008 May; 22(8):993-4. PubMed ID: 18453861
    [No Abstract]   [Full Text] [Related]  

  • 77. Characterization of recombinant influenza A virus as a vector for HIV-1 p17Gag.
    de Goede AL; Boers PH; Dekker LJ; Osterhaus AD; Gruters RA; Rimmelzwaan GF
    Vaccine; 2009 Sep; 27(42):5735-9. PubMed ID: 19647812
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Protection in mice immunized with a heterologous prime-boost regime using DNA and recombinant pseudorabies expressing TgSAG1 against Toxoplasma gondii challenge.
    Shang L; Liu Q; Liu W; Men J; Gao S; Jiang L; Wang Z; Zhai Y; Jin H; Lian H; Chen C; Xia Z; Yuan Z; Zhu XQ
    Vaccine; 2009 May; 27(21):2741-5. PubMed ID: 19428887
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Improved HIV-1 specific T-cell responses by short-interval DNA tattooing as compared to intramuscular immunization in non-human primates.
    Verstrepen BE; Bins AD; Rollier CS; Mooij P; Koopman G; Sheppard NC; Sattentau Q; Wagner R; Wolf H; Schumacher TN; Heeney JL; Haanen JB
    Vaccine; 2008 Jun; 26(26):3346-51. PubMed ID: 18467010
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Cynomolgus macaques immunized with two HIV-1 Tat stabilized proteins raise strong and long-lasting immune responses with a pattern of Th1/Th2 response differing from that in mice.
    Turbant S; Martinon F; Moine G; Le Grand R; Léonetti M
    Vaccine; 2009 Aug; 27(39):5349-56. PubMed ID: 19607953
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.